{"title":"Monitoring the efficacy of antimalarial drugs (2015)","nid":761,"vid":4278,"created":1622112931,"changed":1626693502,"field_accordian_header":[{"field_accordian":[{"field_title":"All malaria programmes should","field_content":"All malaria programmes should regularly monitor the therapeutic efficacy of antimalarial drugs using the standard WHO protocols.<br>\n&nbsp;\n<p class=\"statement\" style=\"background-color:rgb( 102 , 204 , 255 );  padding-left: 15px; padding-right: 15px; padding-top: 8px; padding-bottom: 5px;\"><span style=\"color:#0000cd\"><em>Good practice statement<\/em><\/span><\/p><\/tbody>\n","justification":null,"practical_info":"<p>Routine monitoring of antimalarial drug efficacy is necessary to ensure effective case management and for early detection of resistance. WHO recommends that the efficacy of first- and second-line antimalarial treatments be tested at least once every 24 months at all sentinel sites. Data collected from studies conducted according to the standard protocol inform national treatment policies.\u00a0<\/p><p>Please refer to the <a href=\"https:\/\/www.who.int\/teams\/global-malaria-programme\/case-management\/drug-efficacy-and-resistance\/tools-for-monitoring-antimalarial-drug-efficacy\">tools for monitoring antimalarial drug efficacy<\/a>\u00a0<cite class=\"magic-cite\" data-ref-id=\"362617\" data-label=\"\">[146]<\/cite>\u00a0and\u00a0<a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789241597531\">Methods for surveillance of antimalarial drug efficacy<\/a>\u00a0<cite class=\"magic-cite\" data-ref-id=\"362765\" data-label=\"\">[147]<\/cite>\u00a0which\u00a0includes tools and materials to conduct routine therapeutic efficacy studies (TES). It is a reference for national programmes and investigators conducting routine surveillance studies to assess the efficacy of medicines that have already been registered.<\/p><p>Additional references include:\u00a0<\/p><ul><li><a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789241596305\">Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations<\/a>\u00a0<cite class=\"magic-cite\" data-ref-id=\"362627\" data-label=\"\">[148]<\/cite><\/li><li><a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240012813\">Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019)<\/a>\u00a0<cite class=\"magic-cite\" data-ref-id=\"362733\" data-label=\"\">[149]<\/cite><\/li><\/ul>","field_icon":null}],"field_header":"All malaria programmes should"}],"field_content_type":{"tid":9,"name":"Accord","class":"accord"},"field_left_right_navigation":1,"field_operational_":[{"field_image":"","field_link":"","field_title":null}],"field_recommendations":1,"recommendation":"<p>All cases of suspected malaria should have a parasitological test (microscopy or Rapid diagnostic test (RDT)) to confirm the diagnosis.<br \/>\r\nBoth microscopy and RDTs should be supported by a quality assurance programme.<br \/>\r\n<font color=\"#4090CF\"><em>Good practice statement<\/em><\/font><\/p>\r\n","recommendation_title":"Rapid diagnostic test (RDT)","field_recommendation_api_url":"https:\/\/api.magicapp.org\/api\/v1\/recommendations\/?sectionId=78117","field_references":null,"field_tags":[{"tid":66,"name":"Recommendations for case management"},{"tid":42,"name":"Drug efficacy & resistance"}]}